Gossamer Bio Announces $212 Million Private Placement Financing
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Evercore ISI Downgrades Gossamer Bio Inc. (GOSS) to In Line, 'Long Path Ahead'
July 20, 2023 11:37 AM EDTEvercore ISI analyst Josh Schimmer downgraded Gossamer Bio Inc. (NASDAQ: GOSS) from Outperform to In Line with a price target of $4.00 (from $6.00).
The analyst comments "GOSS reported an initial look at the P2 OLE data for seralutinib in PAH, along with a large financing... More
